M ore than 600 000 percutaneous coronary re- vascularization procedures were performed worldwide in 1993. Despite extensive investigation into a variety of adjunctive therapies and mechanical techniques during the past 15 years, it can be anticipated that 30% to 50% of patients with successfully treated coronary lesions will develop recurrent stenoses (restenosis) over the ensuing 3 to 6 months. 1 The cost of treating patients who will require repeat revascularization will exceed 2500 lives and $3.5 billion. 2 The importance of this problem is magnified by the fact that the process of restenosis following vascular injury may also serve as a paradigm for atherosclerosis, a disease nearly endemic to Westernized civilizations.
Recent pathological3'4 and intravascular ultrasound5,6 studies have suggested that the pathogenesis of restenosis is multifactorial. A dominant process leading to luminal renarrowing of many lesions may be neointimal hyperplasia, and investigations in animal models have characterized this mechanism of arterial "response to injury,"7,8 thereby permitting rational approaches to its prevention. Other mechanisms that are variably important, however, include angiographically inapparent inadequate result, elastic vessel recoil, and mural thrombosis (Fig 1) .
Against this complex process, many of the new devices for percutaneous revascularization have been developed and advocated, including intraluminal stents, lasers, and atherectomy catheters. Unfortunately, observational series and a few controlled trials using these techniques have generally demonstrated restenosis rates that are not dissimilar from those obtained with conventional balloon angioplasty.9-'7 The recent STRESS and BENESTENT trials18"19 have shown significant reductions in restenosis rates using the PalmazSchatz stent, albeit in a relatively select group of patients and with a significant risk of hemorrhagic or thrombotic complications; these findings reinforce the suggestion, however, that an inadequate initial result or elastic recoil may contribute to restenosis in certain settings.
Pharmacological therapy has not fared better than new devices for the treatment of restenosis. Numerous pharmacological agents have been tested which, by virtue of their effects in reducing neointimal proliferation in one or more animal models, might be expected to favorably influence different components of the arterial response to injury in humans. However, clinical trials with these drugs have yet to demonstrate an unequivocal reduction in the incidence of restenosis. 20 These disappointing results may be due in part to interspecies differences in the process of neointimal proliferation in humans and animal models21 or to the incomplete role of neointimal hyperplasia in the causation of human restenosis.3-5 Modification of the mode of administration of pharmacological agents, like by local delivery, would not be expected to yield substantial incremental benefit under such circumstances, whereas mechanical techniques such as intraluminal stenting may be efficacious. However, many of the failures of pharmacological therapy for restenosis in humans relative to animal models may be related to systemic intolerance of doses required to achieve local beneficial effects or difficulty in providing controlled administration of the drugs for adequate periods of time. For example, both cilazapril and enoxaparin have been shown in animal models to potently inhibit neointimal proliferation following arterial injury, 22 '23 yet each has failed to reduce the angiographic restenosis rate in human placebo-controlled trials. 24'25 However, dosages of these agents (adjusted for body weight) in animal studies were 10-to 70-fold higher than those used in the human trials.
Interest has accordingly shifted away from systemically administered agents for prevention of restenosis to local administration of potentially useful compounds directly to the site of arterial injury following coronary angioplasty. There are several possible advantages to this form of therapy. First, local drug delivery would allow very high local concentrations of drug to be achieved, even of agents that are rapidly degraded when administered systemically. Second, by concentrating the drug at the target site without substantial systemic dosing, systemic adverse effects can be minimized. Finally, with certain forms of local delivery, prolonged administration or residence time of drug may be achievable. either constant low-level electric current to push charged molecules through the skin or millisecond pulses to induce changes in the skin to allow passage of drug, respectively). [27] [28] [29] Local drug delivery has been used for a number of noncardiac applications in humans.30 A progesteronereleasing intrauterine device (Progestasert) releases steroid locally over a period of more than 1 year from its polymer reservoir coating. Polymer implants containing very low doses of tetracycline have been used to locally treat periodontal disease. Sustained local delivery of pilocarpine for the treatment of glaucoma has been achieved using a polymer reservoir (Ocusert) designed to float in the conjunctival cul-de-sac. Polymeric disks containing chemotherapeutic agents are under clinical investigation as postsurgical local therapy for brain tumors.
Drug-impregnated controlled-release polymeric matrices have been used experimentally in animal models for the treatment of various cardiovascular disorders, including ventricular arrhythmias and bioprosthetic heart valve calcification.31,32 A local drug delivery device that has been applied clinically for a cardiovascular indication is the steroid eluting pacemaker lead (Medtronic, Inc). The corticosteroid dexamethasone is released over a period of months to years from a silicone polymer reservoir in the metallic tip of this pacemaker lead directly to the site of endocardial pacing, thus attenuating the fibrosis and concomitant rise in pacing thresholds that typically accompany long-term endocardial pacing. 33 Experimental Studies of Local Delivery for Restenosis Several experimental studies in small-animal models have provided "proof of concept" of local delivery for the prevention of the myointimal response that contributes to restenosis. Most of these experiments have used drug delivery from polymers or other reservoirs surgically implanted exterior to the injured vessel, with "inward" diffusion of drug from the adventitia to the media and neointima. Although these techniques of local drug delivery are not practical for treatment of restenosis in humans, for whom placement of drug reservoirs external to the coronary artery is not feasible, such experimental studies have allowed the principle of local drug delivery to be tested.
In the first study to explore the effectiveness of local delivery for restenosis, Edelman and colleagues34 treated rats that had been subjected to carotid artery injury with placebo, heparin delivered intravenously, heparin administered from a polymer matrix implanted under the dorsal skin, or heparin eluted locally from a polymer matrix placed adjacent to the injured carotid artery. Although both intravenous and local heparin delivery markedly diminished neointima formation compared with placebo, local delivery was associated with no change in activated partial thromboplastin time (aPTT), whereas intravenous delivery resulted in significant systemic anticoagulation. This study demonstrated that local drug delivery could produce a beneficial effect on the arterial response to injury that may be uncoupled from unwanted systemic effects.
More recently, Simons and associates35 treated rats after carotid injury with antisense oligonucleotides to the proto-oncogene c-myb, administered from an adventitial "pluronic" polymer. Vessels Other soluble substances that have been used in the evaluation of local drug delivery include fluoresceinated heparin4' or marker dyes.42 During perforated balloon delivery, green dye appears to be transported by bulk convection to sites of tissue disruption and intramural vascular spaces (vasa vasorum or plaque neovascularization), with little penetration into the arterial tissue itself. Fluorescence following local administration of fluoresceinated heparin, in contrast, has been demonstrated to be distributed throughout the media into the adventitia, although this agent was found to be toxic to arterial medial cells, regardless of infusion pressure, in at least one study.4' In addition, no technique to quantitatively assess tissue uptake with these substances has been reported. In an effort to overcome the limitations of washout via the vasa vasorum of soluble tracers such as HRP, heparin, or dye, nondiffusable polymer microparticles have also been injected directly into the vascular wall. 45 Although this technique has thus far been used only for qualitative assessment of local delivery, potential advantages of microparticle injection as a means of drug delivery include the demonstrated prolonged retention (14 days) throughout the media and adventitia, concentrated along planes of vascular dissection and injury. Each of these means of assessing macromolecular transfer suffers, however, in that they fail to provide relevant data regarding the retention and local metabolism of prospective antirestenosis agents.
Delivery Balloon Catheters
Several designs of local delivery balloon catheters are under investigation. The double-balloon catheter (USCI Division of C.R. Bard, Inc) was the first percutaneous drug delivery device.43 This catheter is passed to the treatment site over an intra-arterial guidewire, in a manner analogous to that with an angioplasty balloon. By inflating two small balloons proximal and distal to the vessel segment to be treated, drug can be instilled through a small hole into the chamber thus formed between the balloons (Fig 2A) . Although this device produces minimal trauma at the chamber site, prolonged dwell times are required to achieve significant drug levels by passive diffusion, thus rendering this device impractical for coronary arteries due to distal myocardial ischemia. In addition, although the doubleballoon catheter is suitable for peripheral vessels, the occurrence of sidebranches every 2 to 4 mm in coronary arteries46 results in loss of infusate when the device is used in the coronary tree. To overcome some of the limitations of the double balloon, the Wolinsky perforated-balloon catheter (USCI Division of C.R. Bard, Inc) was developed (Fig 2B) . 41 With twenty-eight 25-,m holes drilled by a laser into a noncompliant balloon, inflation of the balloon causes streaming of infusate through the holes into the apposed vessel wall. This catheter has been shown to result in solute transfer throughout the arterial media and into the adventitia, with the depth of delivery related to infusion pressure. 41 The chief disadvantage of this device is the potential for vascular trauma from the fluid jets, an effect that also appears to be related to infusate pressure. Only 5% of canine arteries treated with this catheter ex vivo in one study had no apparent traumatic effects.47 Such acute trauma, ranging from disruption of elastic laminae to dissection or frank arterial perforation, likely also has significance in terms of long-term sequelae, with greater acute injury translating to a greater long-term arterial neointimal response in animal models. 48 An additional limitation of this device arises from the tendency of the perforations to become intermittently obstructed, resulting in nonhomogeneous solute delivery.
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A microporous balloon (Cordis Corp) was designed to limit the trauma induced by the perforated balloon ( Fig 2C) . Instead of discrete 25-gm holes, this balloon material consists of a membrane with thousands of pores with a diameter of <1 ,um. Administered solute "sweats" from the microporous membrane without jet effects, substantially enhancing the homogeneity of infusion and reducing the potential for arterial injury. 47 Other delivery catheters have been designed to allow balloon dilation with the same device that is used for drug delivery or to maintain distal myocardial perfusion during drug administration. The channel catheter (Boston Scientific Corp) consists of a central angioplasty balloon surrounded on its exterior surface by 24 channels, each with a single 100-,um hole through which drug is delivered (Fig 2D) , thus separating the chambers used for lesion dilation and drug infusion.49 As low infusion pressures appear to minimize vascular trauma, this design allows balloon inflation pressure to be dissociated from drug infusion pressure and permits the catheter to be used for both high-pressure lesion dilation and low-pressure drug infusion. This arrangement particularly simplifies the procedure of postangioplasty local drug delivery, in that exchange of a dilation for a delivery catheter is unnecessary. A similar design is used in the Transport coronary angioplasty catheter (Cardiovascular Dynamics), which consists of an inner balloon for lesion dilation and an outer porous balloon for drug infusion.50 The Dispatch delivery catheter (SciMed Life Systems Inc), recently approved by the Food and Drug Administration for intracoronary drug infusion, uses a helical balloon design that allows infused drug to be held against the arterial wall in the spaces formed between the helices while distal coronary blood flow is maintained through a central lumen ( Fig  2E) . This device thus functions effectively as a "temporary stent" during drug delivery, allowing periods of infusion in excess of 30 to 60 minutes without clinical evidence of resultant myocardial ischemia.
As an alternative technique to allow lesion dilation with the same catheter used for drug delivery, angioplasty balloons have also been coated with a thin layer of hydrophilic polyacrylic acid polymer (Hydrogel, Boston Scientific Corp), which can act as a drug-absorbing sponge. Once loaded with drug, the catheter is introduced into the coronary artery, and the drug is "pressed" into the arterial wall during balloon inflation.51 This -balloon catheter, although prolonged dwell times achievable with autoperfusion devices such as the Dispatch catheter may prove to be particularly desirable. In the porcine coronary artery model, local vessel wall transport of the tracer HRP by the microporous balloon was 8-to 40-fold more efficient than administration by more conventional techniques, such as intracoronary or intravenous infusion.53 Nevertheless, absolute efficiency (medial tracer concentration divided by infusate concentration, corrected for extracellular fluid partition coefficient of the media) may be as low as 1% to 2% in nondiseased coronary arteries; the presence of atherosclerotic plaque likely will modify drug uptake with this and other delivery devices, as will the increased density of vasa vasorum present in advanced atherosclerotic disease. 54 Homogeneity of drug transfer by delivery balloon catheters is likely dependent on a variety of factors, including the number and propensity of perforations to become obstructed and the presence or absence of discrete fluid jets. In animal models, tracer concentrations are typically greatest initially at the luminal aspect of the media53; interestingly, however, HRP delivered even to the superficial (luminal) media by a Hydrogelcoated balloon appears to washout "in waves" into the adventitia within 6 hours (R. McKay, MD, Hartford Hospital, personal communication), perhaps via vessels draining the vasa vasorum. In addition, changes induced in the vascular wall by atherosclerotic disease and the extent of preexistent or induced vascular wall disruption also appear to influence the homogeneity of transport, with infusate likely preferentially transported along dissection planes (Fig 3) . 45 The potential for prolonged drug residence at a target site following local delivery from a balloon catheter appears to be a function of the characteristics of the administered agent, rather than of the delivery device. For certain agents, depending on solubility, molecular size, or the presence of binding or uptake sites within the tissue, retention within the arterial wall may be quite prolonged. When severe cellular inflammation and destruction of vessel architecture.
In contrast to these data, other reports have suggested that at least some polymers may be biocompatible within the coronary vasculature. A group at Duke University has developed an entirely biodegradable stent composed of a high molecular weight poly-l-lactic acid (PLLA) (Fig 4A) Other Potential Targets Other factors potentially located along a common pathway include the variety of growth factor-related tyrosine kinase receptors'07'108 ( Fig 5) and the generation of extracellular matrix, which makes up the vast bulk of the mature restenotic tissue.86 Transforming growth factor-,B appears to play a major role in matrix formation, but it may be too multifunctional to be a good target for inhibition.'09 Basic FGF is known to stimulate smooth muscle cell proliferation"10""11 and has been targeted successfully in several restenosis models."110'11 Other potential inhibitors noted to be effective in at least one model include corticosteroids,36 interferon-a and interferon-y,"12-1"4 HMGCoA reductase inhibitors,1'5 and a variety of antioxidants.116
Timing and Retention
Given that the cascade of events leading to restenosis takes place over a time span of weeks to months, 85, 86, 117118 it is possible that pharmacological inhibition must be active for a similar time period. Agents targeted at early events (eg, platelet deposition or thrombus formation) may need to be present before or at the time of injury but possibly only for a short time thereafter, whereas inhibitors of late events (eg, matrix formation) will likely need to be active later and for long periods of time. The proliferative process may "escape" if an inhibitor is present for insufficient time, as has been described for locally delivered hirudin and some antisense oligonucleotides (R. Rosenberg, MD, PhD, Beth Israel Hospital, personal communication). As the logistics of clinical practice will likely dictate that local administration of drugs be performed at the time of percutaneous revascularization, the choice of delivery device and vehicle will need to be tailored to the residence time adequate to a specific targeted event.
Possible Risks
At present, the risk of inhibition of local wound repair is largely conjectural. Rab and colleagues"19 have reported delayed aneurysm formation in patients treated with metallic stents and systemic steroids and colchicine. One might postulate that the trend toward increased incidence of late sudden death after directional atherectomy noted in the CAVEAT study"' may have been due to medial weakening (from partial resection) and rupture, but this is highly speculative. Nevertheless, the possibilities of aneurysm formation, stasis thrombosis, and even rupture must be considered.
Patient and Lesion Selection
Recent advances with intravaseular ultrasound5'520 and molecular biologyl2l provide hope that antirestenosis therapy may be patient and lesion "tailored," ie, based on the most likely etiologies of restenosis in a particular situation. For example, preliminary data suggest that balloon dilatation of a concentric plaque without a resultant dissection evident to intravascular ultrasound appears to be associated with a high incidence of restenosis,'20 probably via recoil.5 This finding would imply that measures to prevent recoil, such as stent placement, or to change vessel wall compliance might be useful. Conversely, in situ hybridization of lesion specimens removed by directional atherectomy staining for the ,B isoform of nonmuscle myosin heavy chain have been found to be associated with a high likelihood of restenosis,'12 probably due to exuberant neointima formation. Therefore, if a "frozen section" or rapid assay technique for this or another predictor of proliferation could be found to be reliable, especially aggressive antiproliferative treatment could be initiated in appropriate patients.
Development and Approval
Traditionally, pharmacologics (drugs) and devices (eg, angioplasty balloons) have been evaluated by different standards and regulatory bodies at the Food and Drug Administration. Indeed, little precedent except for steroid eluting pacemaker leads has been set for combined drug-device technologies. The guidelines for Investigational Device Exemption and Pre-Market Approval for devices, last standardized in 1989, are under revision, perhaps to be finalized by late 1994. Although the Food and Drug Administration acknowledges that drug-device combinations intended to reduce restenosis will soon need to be evaluated, this class of agents is not even part of the 1994 review. It is of some concern that guidelines for approval remain vague and therefore approval may be delayed for any of this class of agents that may become highly promising in 1994 through 1995.
Future Directions
The pathogenesis of restenosis is complex, involving incomplete mechanical displacement of atherosclerotic plaque and processes fundamental to wound healing. Prevention of restenosis, then, is likely to be equally complex and will be required to account for the multiple pathways of restenosis. Local delivery of selected agents to impair or modify myointimal proliferation has the intuitive appeal of achieving necessarily high tissue concentrations without the expected toxicity from systemic application. Substantial progress has already been made toward achieving the ideal of efficient, atraumatic intraluminal drug delivery using local delivery balloons, and clinical investigations to critically assess and compare these devices have recently been initiated.
Among the challenges for the future in this field will be the development of methods of achieving prolonged drug residence times and enhanced specificity and efficiency of cellular targeting and uptake. The principles of polymer science are only beginning to be applied in a methodical manner to the problems of intravascular drug delivery, and the potential for using controlledrelease polymeric systems for the prevention of restenosis will depend on the identification of polymers that provide sustained, predictable drug release kinetics without promoting thrombosis or inflammation. Optimization of polymer stent configurations or the loading Lincoff et al Local Drug Delivery 2081 characteristics and/or sizes of polymer particles, as well as the use of "biopolymers" or other novel compounds as drug delivery vehicles, can be expected to further enhance tissue compatibility and the efficiency and homogeneity of drug delivery. Extensive investigation into the various potential vectors for intracellular or gene delivery, particularly the viral vectors, will be required to answer important questions regarding practicality and risks for toxicity, persistent infection, or carcinogenesis; such techniques could be applied clinically for prevention of restenosis only if there is sufficient evidence that the therapy will not be "worse than the disease."
Finally, despite the difficulties in extrapolating results from animal models to the clinical treatment of restenosis, local delivery of various pharmacological agents will need to be studied experimentally to identify potentially promising drugs (or combinations) and their most suitable methods of local administration. Refinement of techniques for assessment of individual target lesions will aid in selection of the optimal pharmacological agents and perhaps adjunctive mechanical revascularization techniques to fully control the restenotic response in each patient. It can be anticipated that a better fundamental understanding of the processes involved in restenosis and a systematic approach to this problem by local drug delivery will yield superior clinical results, compared with the previous "shotgun" approaches to the prevention of restenosis.
